Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nexavar, developed by Bayer and Onyx Pharmaceuticals, has been granted orphan drug status for the treatment or liver cancer by the FDA. A similar designation has been granted by the European Commission.
Subscribe to our email newsletter
US orphan drug designation aims to encourage the development of drugs involved in the diagnosis, prevention or treatment of a medical condition affecting fewer than 200,000 people in the country. Among other things, the designation grants US market exclusivity to a drug for a particular indication for a seven-year period if the sponsor complies with certain FDA specifications.
In 2004, investigators reported that in a phase II single agent study, 43% of patients treated with Nexavar (sorafenib) experienced stable disease for at least four months and an additional 9% of patients experienced tumor shrinkage. The toxicity profile of Nexavar was similar to previously reported safety analysis in patients with renal cell carcinoma.
A phase III trial of Nexavar administered as a single agent is ongoing. It is designed to measure differences in overall survival, time-to-symptom progression and time-to-tumor progression of Nexavar versus placebo in liver cancer patients.
A randomized phase II trial for liver cancer patients to evaluate the efficacy of Nexavar in combination with the chemotherapeutic agent doxorubicin is also ongoing.